IL-6 receptor inhibition with tocilizumab reduces disease activity in patients with rheumatoid arthritis with inadequate response to a range of DMARDs: The TOWARD study 71st Annual Scientific Meeting of the American-College-of-Rheumatology/42nd Association-of-Rheumatology-Health-Professionals Genovese, M., McKay, J., Nasonov, E., Myster, E., da Silva, N., Alecock, E., Woodworth, T., Gomez-Reino, J. WILEY-LISS. 2007: 4309–10

View details for Web of Science ID 000251781200185